| Gatifloxacin for TB R Rustomjee, C Lienhardt, T Kanyok, GR Davies, J Levin, T Mthiyane, ... A phase II study of the sterilising activities of ofloxacin, gatifloxacin …, 2008 | 447* | 2008 |
| Clofazimine: current status and future prospects MC Cholo, HC Steel, PB Fourie, WA Germishuizen, R Anderson Journal of antimicrobial chemotherapy 67 (2), 290-298, 2012 | 383 | 2012 |
| The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis B Blomberg, S Spinaci, B Fourie, R Laing BULLETIN-WORLD HEALTH ORGANIZATION 79 (1), 61-68, 2001 | 318 | 2001 |
| Respiratory tuberculosis in childhood: the diagnostic value of clinical features and special investigations HS Schaaf, N Beyers, RP Gie, ED Nel, NA Smuts, FE Scott, PR Donald, ... The Pediatric infectious disease journal 14 (3), 189-194, 1995 | 224 | 1995 |
| Inhaled drug therapy for treatment of tuberculosis A Misra, AJ Hickey, C Rossi, G Borchard, H Terada, K Makino, PB Fourie, ... Tuberculosis 91 (1), 71-81, 2011 | 195 | 2011 |
| Molecular analysis of katG gene mutations in strains of Mycobacterium tuberculosis complex from Africa WH Haas, K Schilke, J Brand, B Amthor, K Weyer, PB Fourie, G Bretzel, ... Antimicrobial agents and chemotherapy 41 (7), 1601-1603, 1997 | 186 | 1997 |
| Immunization by a bacterial aerosol L Garcia-Contreras, YL Wong, P Muttil, D Padilla, J Sadoff, J DeRousse, ... Proceedings of the National Academy of Sciences 105 (12), 4656-4660, 2008 | 177 | 2008 |
| Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model L Garcia-Contreras, J Fiegel, MJ Telko, K Elbert, A Hawi, M Thomas, ... Antimicrobial agents and chemotherapy 51 (8), 2830-2836, 2007 | 164 | 2007 |
| Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline MC Cholo, MT Mothiba, B Fourie, R Anderson Journal of Antimicrobial Chemotherapy, dkw426, 2016 | 149 | 2016 |
| Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis AS Dharmadhikari, M Kabadi, B Gerety, AJ Hickey, PB Fourie, E Nardell Antimicrobial agents and chemotherapy 57 (6), 2613-2619, 2013 | 140 | 2013 |
| Pyrazinamide Resistance among South African Multidrug-Resistant Mycobacterium tuberculosis Isolates M Mphahlele, H Syre, H Valvatne, R Stavrum, T Mannsåker, T Muthivhi, ... Journal of clinical microbiology 46 (10), 3459-3464, 2008 | 140 | 2008 |
| The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis FA Sirgel, PB Fourie, PR Donald, N Padayatchi, R Rustomjee, J Levin, ... American journal of respiratory and critical care medicine 172 (1), 128-135, 2005 | 138 | 2005 |
| Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. MM McGregor, P Olliaro, L Wolmarans, B Mabuza, M Bredell, MK Felten, ... American journal of respiratory and critical care medicine 154 (5), 1462-1467, 1996 | 135 | 1996 |
| Next-generation ion torrent sequencing of drug resistance mutations in Mycobacterium tuberculosis strains LT Daum, JD Rodriguez, SA Worthy, NA Ismail, SV Omar, AW Dreyer, ... Journal of clinical microbiology 50 (12), 3831-3837, 2012 | 112 | 2012 |
| The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis K Dheda, T Gumbo, G Maartens, KE Dooley, M Murray, J Furin, ... The Lancet Respiratory Medicine 7 (9), 820-826, 2019 | 107 | 2019 |
| Activity of 7-methyljuglone derivatives against Mycobacterium tuberculosis and as subversive substrates for mycothiol disulfide reductase A Mahapatra, SPN Mativandlela, B Binneman, PB Fourie, CJ Hamilton, ... Bioorganic & medicinal chemistry 15 (24), 7638-7646, 2007 | 103 | 2007 |
| Procedures for developing a simple scoring method based on unsophisticated criteria for screening children for tuberculosis PB Fourie, PJ Becker, F Festenstein, GB Migliori, J Alcaide, M Antunes, ... The International Journal of Tuberculosis and Lung Disease 2 (2), 116-123, 1998 | 102 | 1998 |
| Fixed-dose combination drugs for tuberculosis: application in standardised treatment regimens B Blomberg, B Fourie Drugs 63 (6), 535-553, 2003 | 100 | 2003 |
| Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption GA Ellard, PB Fourie The International Journal of Tuberculosis and Lung Disease 3 (11), S301-S308, 1999 | 98 | 1999 |
| Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market G Pillai, PB Fourie, N Padayatchi, PC Onyebujoh, H McIlleron, PJ Smith, ... The International Journal of Tuberculosis and Lung Disease 3 (11), S309-S316, 1999 | 96 | 1999 |
